INFLA HARMONY™: Joint & Mobility Support 50+

Osteoarthritis combines wear and destruction of joint cartilage, but it is not limited to cartilage: according to Assurance Maladie, “all the tissues of the joint undergo changes.”

A point often misunderstood: it is not simply ageing. “The normal ageing of cartilage over a lifetime does not, on its own, cause osteoarthritis. Osteoarthritis is a condition in its own right.”

Source (French agency, quotes translated from French): Assurance Maladie, ameli.fr, accessed 21 August 2026.

Age is a risk factor, but it does not explain everything, and cartilage ageing alone is not enough to cause the condition.

Assurance Maladie cites other factors: excess weight and obesity, which “put strain on the joints”; a history of trauma, such as “a meniscus injury” or “a severe sprain”; occupational strain, in particular “working in a crouched or kneeling position, or frequently carrying heavy loads”; “poorly controlled, intensive practice of certain sports”; and genetic factors “firmly established for osteoarthritis of the hand and knee.”

Several of these factors can be changed.

Source (French agency, quotes translated from French): Assurance Maladie, ameli.fr, accessed 21 August 2026.

Outside of painful flare-ups, Assurance Maladie is clear: “it is important to stay active.” It recommends walking daily and “favouring swimming over running, which encourages micro-trauma.”

Physical activity ranks first among the non-drug measures recommended in the management of osteoarthritis.

This recommendation applies only during calm periods. The next question matters.

Source (French agency, quotes translated from French): Assurance Maladie, ameli.fr, accessed 21 August 2026.

The advice reverses. During a congestive flare-up, Assurance Maladie states that “you should temporarily stop all physical activity” and “put the joint in relative rest.” It specifies: “avoid walking when it hurts and avoid standing for too long.”

Activity resumes once the painful episode ends. This is an essential nuance: the advice to “keep moving” is wrong if applied during a flare-up.

Source (French agency, quotes translated from French): Assurance Maladie, ameli.fr, accessed 21 August 2026.

Only one nutritional lever is established by institutional sources: weight loss in cases of excess weight. Assurance Maladie recommends “taking the strain off your joints to slow their deterioration by losing weight if you are overweight.”

No food, spice or specific diet is the subject of any institutional recommendation in this context.

Source (French agency, quote translated from French): Assurance Maladie, ameli.fr, accessed 21 August 2026.

No, and this is not a note of caution. ANSES, France’s food safety agency, states it as a definition: “A food supplement is not a medicine, and can therefore not, by definition, claim any therapeutic effect.”

European Directive 2002/46/EC also prohibits attributing to these products “properties of preventing, treating or curing” a disease.

A supplement therefore replaces neither a diagnosis, nor a treatment, nor the advice of a doctor or pharmacist.

Sources (French agency, quotes translated from French, plus EU directive): ANSES; Directive 2002/46/EC, Article 6. Accessed 21 August 2026.

Glucosamine and chondroitin account for by far the most clinical research. Curcumin, collagen, boswellia and omega-3s form a second, considerably less documented group.

The volume of research says nothing about the outcome. On glucosamine and chondroitin, France’s National Authority for Health (HAS) concluded in 2013 that “their effects on the pain and functional discomfort linked to osteoarthritis are minor” and that “the medical benefit provided by these medicines is insufficient.” They are no longer reimbursed by Assurance Maladie.

For curcumin, the deciding question is not the ingredient but its form: standard turmeric is very poorly absorbed, which contributes to highly variable results from one study to another.

Sources (French institutions, quotes translated from French): HAS, Transparency Committee, 11 July 2013; Assurance Maladie. Accessed 21 August 2026.

For two factual reasons.

First, EFSA concluded that “a cause and effect relationship has not been established” between glucosamine consumption and joint maintenance, and no claim has been authorised for these substances.

Second, in 2019 ANSES published a safety opinion advising against joint-targeted supplements containing glucosamine or chondroitin sulfate for several populations: people with diabetes or pre-diabetes, asthma, those treated with vitamin K antagonists, those allergic to crustaceans or insects, as well as pregnant or breastfeeding women and children.

Our formula contains neither: these specific contraindications do not apply to it. Its own precautions for use appear in the dedicated tab on this page.

Sources (EU and French agency, quotes translated where noted): EFSA Journal 2011;9(12):2476; ANSES, opinion 2015-SA-0069 of 4 January 2019. Accessed 21 August 2026.

Meta-analyses exist, and they are weak. A 2026 review covering seven meta-analyses rates all of them as “critically low” methodological quality under the AMSTAR-2 tool: of 48 outcomes assessed, 37 rely on critically low-quality evidence, and publication bias is detected in 77% of cases.

The limitations named by the authors are always the same: small sample sizes, weak randomisation and blinding, highly heterogeneous forms of curcumin from one study to another, and follow-up periods mostly under six months.

In other words: there is literature, but it does not support a firm conclusion. We would rather state that.

Source: Frontiers in Pharmacology, 2026, umbrella review of seven meta-analyses. Accessed 21 August 2026.

Four mechanisms combine, and they are well documented: curcumin is practically insoluble in water, it crosses the intestinal wall poorly, it is unstable at physiological pH, and the fraction that is absorbed is immediately processed by the liver and intestine.

ANSES sums it up: “very low oral absorption, rapid metabolism and elimination,” and notes that “most curcumin is found in stools after oral ingestion.” The European Medicines Agency’s assessment report speaks of “poor systemic bioavailability, because of low solubility and poor absorption.”

In practical terms, a 2001 clinical study using doses of 36 to 180 mg of curcumin detected neither curcumin nor its metabolites in the blood or urine of participants.

Sources (French agency, EU medicines agency, and clinical study): ANSES, opinion 2019-SA-0111 of 12 May 2022; EMA/HMPC/329745/2017; Sharma et al., 2001. Accessed 21 August 2026.

A standardised, or titrated, extract is an extract whose content of a given compound is measured and adjusted. The European Medicines Agency defines it as an extract “adjusted within an acceptable tolerance to a given content of constituents.”

The gap with plant powder is considerable: turmeric rhizome contains around 2 to 8% curcuminoids according to ANSES, whereas a purified extract contains more than 95%.

One honest clarification to finish: a standardisation states a content, it says nothing about absorption, and nothing about efficacy. These are three separate questions.

Sources (EU medicines agency and French agency): EMA/HMPC/CHMP/CVMP/287539/2005; ANSES, opinion 2019-SA-0111. Accessed 21 August 2026.

Yes, and it would be dishonest not to state this on the page of a product that contains it.

ANSES has recorded “more than 40 cases of hepatitis occurring between 2002 and 2021 during the consumption of food supplements containing turmeric or curcumin,” nine of which with likely or very likely causality. It advises against the consumption of turmeric by people suffering from disorders of the biliary tract, and states it should be avoided by people treated with anticancer medicines or medicines with a narrow therapeutic margin, such as anticoagulants.

ANSES considers that consumption raises no particular concern as long as it does not exceed 153 mg of curcumin per day for a 60 kg adult. It adds an important caveat: this benchmark “does not apply to formulations whose bioavailability” has been increased. Our formula provides 92 mg of curcuminoids per daily dose, and it uses an encapsulated form: ANSES’s caveat therefore applies to it, which is one more reason to follow the stated dose and seek medical advice if you are on ongoing treatment.

The full precautions for use appear in the dedicated tab on this page.

Source (French agency, quotes translated from French): ANSES, opinion 2019-SA-0111 of 12 May 2022. Accessed 21 August 2026.

Because European Regulation 1924/2006 governs health claims, and those relating to botanical substances have never been settled.

EFSA assessed 4,637 claims between 2008 and 2010, after which the European Commission suspended the procedure: 1,548 claims relating to botanical substances “have been placed on hold by the Commission.” They still are.

The Court of Justice of the European Union confirmed this in its ruling of 30 April 2025 (case C-386/23): “the assessment of health claims relating to botanical substances has been suspended and the list concerning such claims has not yet been drawn up.”

A brand that makes a claim regardless is no better informed than anyone else. It is simply less cautious.

Sources: EFSA, statement of 28 July 2011; CJEU, ruling of 30 April 2025, case C-386/23. Accessed 21 August 2026.

One nuance exists, however, and we apply it. Among the claims still pending are statements relating to joint health, usable under the transitional regime provided for in Article 28 of the Regulation. On this basis, and this basis only, this page states that turmeric and boswellia contribute to joint health. No statement referring to a disease is possible, and you will find none here.

This concerns the length of research protocols, not a timeframe for an effect, which no one is in a position to promise you.

In the literature, trials on boswellia last from 4 to 24 weeks, and those on curcuminoids from 2 weeks to 6 months. The European Medicines Agency’s guidelines for the clinical assessment of osteoarthritis products state, for slow-acting products, that “an evaluation after at least 6 to 12 months may be considered appropriate.”

Sources: BMC Complementary Medicine and Therapies, 2020 and 2022; EMA, CPMP/EWP/784/97 Rev. 1. Accessed 21 August 2026.

Three checks are enough to rule out most vague products.

Check that the amount of each plant or plant preparation is given as a figure, relative to the recommended daily portion: this is a regulatory requirement, not a favour. Then check the standardisation, meaning the stated content of the characteristic compound, without which an amount of extract does not mean much. Finally, check that the daily portion is clearly defined, since every amount relates back to it.

A fraud-control survey also found a high rate of non-compliance in this market, which is a good reason to look at the label rather than the promise.

Sources (EU directive and French decree/authority): Directive 2002/46/EC, Articles 6 and 8; Decree No. 2006-352, Article 12; DGCCRF (French consumer protection authority). Accessed 21 August 2026.

Take 4 capsules a day, with a glass of water, preferably in the morning.

One bottle contains 120 capsules, for 30 days.

It is not recommended in cases of biliary obstruction or biliary function disorders, for pregnant or breastfeeding women, for people with diabetes, or when taking anticoagulants, anticancer medicines or immunosuppressants.

Do not exceed the recommended daily dose. This product is not a substitute for a healthy lifestyle or a varied, balanced diet. Keep out of reach of young children.

If you are on ongoing treatment, seek the advice of a doctor or pharmacist.

Yes. The monthly subscription is €29.90 instead of €39.90, and cancellation is possible at any time.

Every page in this range describes the same product: the same actives, the same amounts, the same 120-capsule bottle, the same dose of four capsules a day. No version is more concentrated than another, none is reserved for a particular profile. What changes from page to page is the angle from which the composition is explained and the list of questions each page takes the time to answer.

This page is written for readers over fifty who prefer to find out early rather than late. The other pages start from a different context, with the same public sources and the same composition: if you still train regularly, if your days are spent sitting, if the discomfort runs down your leg, if this has been going on for months, or the joint supplement page if you would rather start with what this type of product contains.

Whichever page you choose, the full composition is published in the Ingredients tab on this page. If you are on ongoing treatment, seek the advice of a doctor or pharmacist.

On the topic of joints, European regulation authorises one statement under the pending claims: boswellia contributes to the health of joints and bones. This formula provides 307 mg per daily dose, as a concentrated extract standardised to 65% boswellic acids, providing 200 mg of boswellic acids.

Beyond this sentence, nothing more can be stated, by us or by anyone else.

The same framework applies: turmeric contributes to joint health. This formula provides 400 mg of Longvida® curcumin, including 92 mg of curcuminoids, extracted using the patented “Solid Lipid Curcumin Particle” technology.

As ordinary curcumin is very poorly absorbed, it was the form that guided this choice, not the raw quantity. Here again, nothing else can be stated.